Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Wang, Danan ^a   Wang, Qinghui ^a   Shan, Fengping ^a   Liu, Beixing ^a   Lu, Changlong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ARTIFICIAL NEURAL NETWORK; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAYESIAN LEARNING; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; THROMBOCYTE; VALIDATION PROCESS; AGED; EVALUATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RANDOMIZATION; RECEIVER OPERATING CHARACTERISTIC;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROGNOSIS; RANDOM ALLOCATION; RISK ASSESSMENT; ROC CURVE; YOUNG ADULT;

EID: 77955827144     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-251     Document Type: Article

References (37)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107. 10.1046/j.1365-2893.2003.00487.x, 14996343.
2. Alam MM, Zaidi SZ, Malik SA, Naeem A, Shaukat S, Sharif S, Angez M, Khan A, Butt JA. Serology based disease status of Pakistani population infected with Hepatitis B virus. BMC Infect Dis 2007, 7:64. 10.1186/1471-2334-7-64, 1913529, 17597512.
3. Zeng Z, Guan L, An P, Sun S, O'Brien SJ, Winkler CA, . HBV study consortium A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population. BMC Infect Dis 2008, 8:1. 10.1186/1471-2334-8-1, 2238742, 18171470, HBV study consortium.
4. Maddrey W. Hepatitis B: an important public health issue. J Med Virol 2000, 61:362-366. 10.1002/1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I, 10861647.
5. Wei L. Natural history of chronic hepatitis B virus infection: what determines prognosis after cirrhotic decompensation?. J Gastroenterol Hepatol 2008, 23:1631-1632. 10.1111/j.1440-1746.2008.05576.x, 19120855.
6. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M, . Asian-Pacific consensus update working party on chronic hepatitis B Asian-Pacific consensus ststement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005, 25:472-489. 10.1111/j.1478-3231.2005.01134.x, 15910483, Asian-Pacific consensus update working party on chronic hepatitis B.
7. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, . Cirrhosis Asian Lamivudine Multicentre Study Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531. 10.1056/NEJMoa033364, 15470215, Cirrhosis Asian Lamivudine Multicentre Study Group.
8. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001, 344:495-500. 10.1056/NEJM200102153440706, 11172192.
9. Narasimhan G, Sargios TN, Kalakuntla R, Homel P, Clain DJ, Theise ND, Bodenheimer HC, Min AD. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat 2006, 13:783-786. 10.1111/j.1365-2893.2006.00763.x, 17052279.
10. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy: A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173. 10.1016/S0168-8278(86)80075-7, 3958472.
11. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003, 38:427-432. 10.1080/00365520310000825, 12739716.
12. Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, Mak B, Oo AM, Lim SG. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006, 26:666-672. 10.1111/j.1478-3231.2006.01287.x, 16842322.
13. Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, Forouzanfar MH, Abedian S, Tavangar SM, Mohamadkhani A, Ghoujeghi F, Estakhri A, Nouri N, Farzadi Z, Najjari A, Malekzadeh R. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006, 101:2537-2545.
14. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffess in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver International 2008, 28:1408-1416. 10.1111/j.1478-3231.2008.01784.x, 18482268.
15. Ngo Y, Benhamou Y, Thibault V, Ingiliz P, Munteanu M, Lebray P, Thabut D, Morra R, Messous D, Charlotte F, Imbert-Bismut F, Bonnefont-Rousselot D, Moussalli J, Ratziu V, Poynard T. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PloS One 2008, 2(3):e2573.
16. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF, Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005, 42:1437-1445. 10.1002/hep.20960, 16317674.
17. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK, Sung JJ. Identification of chronic hepatitis B patients without signification liver fibrosis by a simple noninvasive model. Am J Gastroenterol 2005, 100:616-623. 10.1111/j.1572-0241.2005.41289.x, 15743360.
18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007, 45:507-539. 10.1002/hep.21513, 17256718.
19. Green M, Bjork J, Forberg J, Ekelund U, Edenbrandt L, Ohlsson M. Comparison between neural networks and multiple logistic regression to predict acute coronary syndrome in the emergency room. Artif Intell Med 2006, 38:305-318. 10.1016/j.artmed.2006.07.006, 16962295.
20. Abbod MF, Catto JW, Linkens DA, Hamdy FC. Application of artificial intelligence to the management of urological cancer. J Urol 2007, 178:1150-1156. 10.1016/j.juro.2007.05.122, 17698099.
21. Wang CH, Mo LR, Lin RC, Kuo JJ, Chang KK, Wu JJ. Artificial neural network model is superior to logistic regression model in predicting treatment outcomes of interferon-based combination therapy in patients with chronic hepatitis C. Intervirology 2008, 51:14-20. 10.1159/000118791, 18309244.
22. Piscaglia F, Cucchetti A, Benlloch S, Vivarelli M, Berenguer J, Bolondi L, Pinna AD, Berenguer M. Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. Eur J Gastroenterol Hepatol 2006, 18:1255-1261. 10.1097/01.meg.0000243885.55562.7e, 17099373.
23. Lampinen J, Vehtati A. Bayesian approach for neural networks-review and case studies. Neural Netw 2001, 14:257-274. 10.1016/S0893-6080(00)00098-8, 11341565.
24. Bedossa P, Poynard T. An algorithm for grading of activity in chronic hepatitis C. The METAVIR co-operative study group. Hepatology 1996, 24:289-293. 10.1002/hep.510240201, 8690394.
25. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230. 10.1016/S0168-8278(03)00171-5, 12873819.
26. Fish KE, Blodgett JG. A visual method for determining variable importance in an artificial neural network model: an empirical benchmark study. J Targ Meas Anal Market 2003, 11:244-254.
27. Dayhoff JE, Deleo JM. Artificial neural network-Opening the black box. Cancer 2001, 91:1616-1635.
28. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117. 10.1053/gast.2003.50013, 12512035.
29. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Internal Med 2008, 47:569-575.
30. Zhang YX, Wu WJ, Zhang YZ, Feng YL, Zhou XX, Pan Q. Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World of Gastroenterol 2008, 14:7117-7121.
31. Yao XQ, Zhu HQ, She ZS. A dynamic Bayesian network approach to protein secondary structure prediction. BMC Bioinformatics 2008, 9:49-61. 10.1186/1471-2105-9-49, 2266706, 18218144.
32. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008, 32:22-39. 10.1016/S0399-8320(08)73991-5, 18973844.
33. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8-19. 10.1186/1476-5926-3-8, 522750, 15387887.
34. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007, 13:525-731.
35. Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, Jun SY, Park CK. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008, 40:267-274. 10.1016/j.dld.2007.10.011, 18055281.
36. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004, 140:189-202.
37. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, Benhamou Y, Bourliere M, de Ledinghen V, . FibroPaca Group Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. Clinical Chemistry 2007, 53:1615-1622. 10.1373/clinchem.2007.085795, 17634213, FibroPaca Group.